Insmed Incorporated
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
 |
return to message board, top of board |
Re: R&D DayLong term risk has switched from being long to being short. As results from EU approval, Japan approval and various trial data for Brensocatib (Covid, Bronchiectasis, Asthma, COPD, etc.) roll in the benefit vs liability continues to accelerate.
|
||||||||||||||||||
|
|
return to message board, top of board |
